PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q1–2025Q4) · Prices as of the 2026-10-02 close
Kwangdong Healthbio turned operating profit positive in 2025 but remains net-loss, with overseas expansion and group synergy under Kwangdong Pharmaceutical still unproven.
2025 revenue was KRW 66.98bn with operating profit of KRW 900mn, turning positive from a 2024 operating loss, but net income remained negative at KRW -640mn.
The company supplies over 300 client brands as an OEM/ODM manufacturer, yet sales to controlling shareholder Kwangdong Pharmaceutical's group accounted for only about 3% of revenue in 2024.
Domestic sales made up roughly 98.5% of revenue, and the company has stated a goal of raising overseas sales, focused on Southeast Asia.
The debt ratio rose from 216.4% in 2022 to 240.1% in 2025, increasing leverage, while parent Kwangdong Pharmaceutical injected capital via a rights offering to reinforce liquidity.
As a KONEX-listed name, trading liquidity and information access remain more limited than KOSDAQ- or KOSPI-listed peers.
Founded in 1992 and listed on KONEX in 2015, Kwangdong Healthbio is a health functional food and cosmetics manufacturer that produces and supplies products for over 300 client brands under an OEM/ODM model.
Its flagship products include processed red ginseng items, deer antler-based health drinks, and probiotic supplements, with most transactions structured as B2B.
The company holds several individually recognized functional ingredients approved by Korea's Ministry of Food and Drug Safety, including a deer antler and Angelica gigas complex extract for prostate health, a rosemary-grapefruit extract complex for UV skin protection, a Moro orange extract powder for body fat reduction, an Andrographis paniculata extract for joint health, and an Angelica gigas-deer antler-astragalus complex for fatigue relief.
In December 2023, Kwangdong Pharmaceutical acquired a 58.74% stake to become the controlling shareholder, after which the company changed its name from BL Healthcare to Kwangdong Healthbio.
The acquisition was intended to let the unit handle Kwangdong Pharmaceutical's health functional food and related material business for group synergy, but as of 2024 sales to the Kwangdong Pharmaceutical and Kwangdong Life & Health group accounted for only about 3% of revenue, indicating group synergy has not yet materialized meaningfully.
The company supplies a diversified client base including Bodyfriend and ENN among various brands, maintaining a B2B supply structure through distribution specialists.
Domestic sales represent roughly 98.5% of revenue, reflecting heavy reliance on the home market, and the company has stated a goal of expanding overseas, focused on Southeast Asia, including participation in the Vitafoods Asia exhibition held in Thailand.
Competitors include major domestic health functional food ODM players such as Novarex, Cosmax NBT, Kolmar BNH, and RP Bio, and relative to these peers Kwangdong Healthbio has a smaller revenue base and has yet to demonstrate stable growth since coming under the Kwangdong group.
| Quarter | Revenue | Operating profit | Op. margin |
|---|
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩63.9B | ₩1.6B | ₩700M | 2.4% | 4.0% | 216.4% |
| 2023 | ₩80.2B | ₩2.6B | ₩600M | 3.3% | 3.2% | 215.2% |
| 2024 | ₩65.5B | -₩1B | -₩2B | −1.5% | −12.3% | 232.4% |
| 2025 | ₩67B | ₩900M | -₩600M | 1.3% | −3.5% | 240.1% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-09-05
On a confirmed consolidated basis, revenue rose from KRW 63.9bn in 2022 to KRW 80.2bn in 2023, a gain of over 25%, before falling back to KRW 65.5bn in 2024 and recovering modestly to KRW 67.0bn in 2025.
Operating profit remained positive in 2022 (KRW 1.56bn) and 2023 (KRW 2.63bn), swung to a loss of KRW -996mn in 2024, then returned to profit at KRW 900mn in 2025. The operating margin fell sharply from 3.3% in 2023 to -1.5% in 2024 before recovering to 1.3% in 2025, still below the 2023 level.
Net income attributable to owners was positive in 2022 (KRW 701mn) and 2023 (KRW 570mn), but swung to a large net loss of KRW -1.96bn in 2024 and remained negative at KRW -641mn in 2025.
The fact that net losses persisted even after the operating turnaround suggests non-operating items such as financial expenses weighed on the bottom line.
Owners' equity fell from KRW 18.05bn in 2023 to KRW 15.93bn in 2024 before rising back to KRW 18.29bn in 2025, reflecting both a narrower net loss and capital raised through Kwangdong Pharmaceutical's participation in a rights offering.
The debt ratio held steady at 216.4% in 2022 and 215.2% in 2023 but climbed to 232.4% in 2024 and 240.1% in 2025, indicating somewhat higher leverage.
Operating cash flow rose from KRW 870mn in 2022 to KRW 3.99bn in 2023, eased to KRW 1.76bn in 2024, then improved again to KRW 3.35bn in 2025, staying positive throughout the period. Overall, 2025 saw both top-line and operating profit improve, but a net loss and a rising debt ratio remain outstanding issues.
Korea's health functional food market was estimated at roughly KRW 6.4 trillion in 2025, up 5.2% year over year, and is projected to grow at a 4.8-6.2% CAGR through 2026-2028, surpassing KRW 7.5 trillion by 2028.
The top revenue categories are probiotics, vitamins/minerals, and omega-3, with personalized and senior-targeted products driving growth.
The market has moved from the double-digit growth seen during the pandemic into a steadier mid-single-digit growth phase, with the top ten companies accounting for about 45% of total sales, indicating a competitive landscape dominated by larger players.
Across the ODM industry, expanding the share of individually recognized functional ingredients is seen as key to margin improvement, while overseas export expansion has become a common growth strategy.
Against this backdrop, listed ODM peers such as Novarex, Kolmar BNH, and Cosmax NBT have relatively larger revenue bases and more diversified overseas channels, while press reports noted that Kwangdong Healthbio's revenue fell 12.9% year over year in the first half of 2025, underperforming its peer group.
However, the confirmed full-year 2025 figures show revenue actually rose modestly for the full year, suggesting second-half improvement offset the weak first half.
As the domestic market matures and product premiumization centered on functionality and safety advances, Kwangdong Healthbio, as a KONEX-listed company, is generally seen as relatively disadvantaged compared to KOSDAQ-listed peers in terms of capital market access and brand recognition.
Citing the typical one-to-two-year lead time to commercialize new ingredients, the company has previously indicated that group synergy would materialize more fully going forward, and in practice the development-to-launch cycle is already operating: a deer antler and Angelica gigas complex extract received individually recognized ingredient approval in July 2023 and was launched through Kwangdong Pharmaceutical in December 2024.
A company representative said it had received a partnership proposal from a major distribution channel regarding an Angelica gigas-deer antler-astragalus complex extract and was in discussions to finalize a core distribution partner, while planning to complete production and delivery systems.
On overseas expansion, the company set a goal of reducing reliance on the domestic market by focusing on Southeast Asia, aiming to raise the overseas revenue share to over 5% within the next year and over 30% within five years.
Toward that goal, it exhibited at Vitafoods Asia, the largest health functional food trade show in the Asia-Pacific region, held in Thailand, and reported continued inbound inquiries from potential clients.
On the financing side, Kwangdong Pharmaceutical participated in a third-party rights offering in October 2025, injecting KRW 3.0 billion, disclosed as being earmarked for working capital such as raw material purchases and payables settlement as well as investment in production automation.
Separately, a disclosure on July 13, 2026 showed that BL Pharmtech, the former controlling shareholder, decided to acquire roughly KRW 1.05 billion worth of Kwangdong Healthbio shares, a development worth watching for potential shifts in the shareholder base.
These plans are based on company statements, however, and actual implementation and timing require confirmation through future disclosures.
The current share price trades at a level below net asset value per share, placing it in a low-premium range relative to book value.
However, with net losses recorded in both 2024 and 2025, a conventional price-to-earnings comparison is difficult to construct, which is a relevant point of reference against other small-cap health functional food and bio-related names on KONEX.
The company does not pay dividends, making a dividend-yield comparison inapplicable. The swing in operating profit from a loss in 2024 to a profit in 2025 is notable in terms of earnings direction, but the continuing net loss and rising debt ratio warrant consideration alongside it from a capital-structure standpoint.
The low trading volume and information asymmetry characteristic of the KONEX market are also factors that can affect how valuation is interpreted.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-09-05
Operating profit turned positive at KRW 900mn in 2025 from a KRW -996mn loss in 2024, while revenue also rose modestly from KRW 65.5bn to KRW 67.0bn. Operating cash flow improved to KRW 3.35bn in 2025 from KRW 1.76bn a year earlier, supporting the cash-generation picture. This can be read as a signal that the 2024 slump may have been driven by temporary factors.
After Kwangdong Pharmaceutical acquired a 58.74% stake to become the controlling shareholder in December 2023, it participated in a KRW 3.0 billion third-party rights offering in October 2025 to support working capital and automation investment.
This shows that parent financial backing has actually functioned during periods of liquidity stress. In July 2026, former controlling shareholder BL Pharmtech also decided to acquire a small stake, opening the possibility of a more diversified shareholder base.
The company holds a range of individually recognized functional ingredients, including a deer antler-Angelica gigas complex, an Andrographis paniculata extract, and an Angelica gigas-deer antler-astragalus complex, providing a basis for higher-margin product development.
Targeting expansion focused on Southeast Asia, it exhibited at the Vitafoods Asia show in Thailand and set a goal of lifting overseas revenue share to above 5% within a year. Whether this ingredient diversification and overseas channel development translates into actual sales is a key point to watch.
Even though operating profit turned positive, net income attributable to owners remained negative at KRW -641mn in 2025. This follows a large net loss of KRW -1.96bn in 2024, marking two consecutive years of net losses. Non-operating expense burdens appear to be offsetting a substantial portion of the operating improvement.
With domestic sales at about 98.5% of the total, overseas diversification has not yet taken hold, and press reports noted that first-half 2025 revenue fell 12.9% year over year, underperforming peers such as Novarex (+37.6%), Cosmax NBT (+9.1%), and RP Bio (+7.9%).
Kolmar BNH also saw revenue decline, but by a smaller margin than Kwangdong Healthbio, according to the same reporting. With domestic health functional food market growth having settled at a moderate pace, competitive intensity could persist.
Even after coming under Kwangdong Pharmaceutical, sales to the Kwangdong Pharmaceutical and Kwangdong Life & Health group made up only about 3% of revenue as of 2024, meaning the expected captive demand effect has not been substantial.
At the same time, the debt ratio rose from about 215-216% in 2022-2023 to 240.1% in 2025, increasing balance-sheet burden. With net losses and rising leverage occurring together, continued reliance on external capital support is possible.
The debt ratio climbed to 240.1% in 2025, and owners' equity of KRW 18.29bn is relatively thin compared with liabilities of KRW 43.9bn. If net losses continue, the company may need to rely on additional external funding or further parent support. A delay in earnings improvement could renew concerns about financial stability.
KONEX has lower trading volume and liquidity than KOSDAQ or KOSPI, along with more limited investor information access. Even small trades can cause outsized price swings, and institutional and fund inclusion is more constrained. These structural characteristics can affect both valuation interpretation and trading convenience.
The health functional food industry is heavily influenced by MFDS approval processes for individually recognized ingredients and regulations on functional labeling and advertising. Ingredient safety issues or quality control problems could negatively affect client contract relationships and brand trust.
There is also execution risk in transitioning from a multi-product, small-batch structure toward fewer products at larger production scale.
The progress toward the company's stated goal of raising overseas revenue share above 5% should be checked. Whether this target is met needs to be verified through future disclosures or IR materials.
Whether BL Pharmtech's roughly KRW 1.05 billion share acquisition is actually completed, and whether it results in any change to the shareholder structure, should be confirmed through follow-up disclosures.
This is when the FY2026 annual business report is expected to be filed on DART, providing an opportunity to check whether net income turns positive, how the debt ratio trends, and how the overseas revenue share has changed.
It is worth confirming whether the individually recognized ingredient partnership with a major distribution channel mentioned by the company results in a final contract, and whether the production and delivery system build-out is completed.
Kwangdong Healthbio showed signs of moving past its 2024 earnings slump by turning operating profit positive in 2025, but net income remains negative, suggesting full normalization will take more time.
With heavy reliance on domestic sales, overseas expansion and the development of higher-margin products using individually recognized ingredients remain key variables for future growth.
Even after coming under Kwangdong Pharmaceutical, the low share of intra-group sales indicates the expected synergy remains limited so far, and the rising debt ratio is a point warranting attention from a financial-structure perspective.
Parent capital support and the recent stake decision by BL Pharmtech appear to be serving as a liquidity backstop. The lower liquidity and information access constraints characteristic of the KONEX market are factors investors should separately weigh.
Going forward, it will be important to continually verify, through future earnings and disclosures, whether the operating turnaround proves durable and whether overseas revenue expansion materializes.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.